Development of the Brazilian anti Schistosomiasis vaccine based on the recombinant fatty acid binding protein Sm14 plus GLA-SE adjuvant

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Tendler, Miriam ^a   Almeida, Marilia ^a   Simpson, Andrew ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Orygen Biotecnologia   (Brazil)

Author keywords

Brazil; Disease of poverty; FABP; Schistosomiasis; Sm14; Vaccine

Indexed keywords

BACTERIAL VECTOR; FATTY ACID BINDING PROTEIN; GLUCOPYRANOSYL LIPID ADJUVANT STABLE EMULSION; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; SCHISTOSOMA VACCINE; SM14 VACCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BRAZIL; CELLULAR IMMUNITY; DRUG PURIFICATION; ESCHERICHIA COLI; EXPRESSION VECTOR; FERMENTATION; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE GENE; ION EXCHANGE CHROMATOGRAPHY; KOMAGATAELLA PASTORIS; MOLECULAR CLONING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POLYACRYLAMIDE GEL ELECTROPHORESIS; SCHISTOSOMIASIS; SHORT SURVEY; VACCINATION; VACCINE PRODUCTION; WESTERN BLOTTING;

EID: 84934291624     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00218     Document Type: Short Survey

References (46)

1. World Health Organization. Report of an Informal Consultation on Schistosomiasis Control. (2010). Available from: http://www.who.int/schistosomiasis/epidemiology/PZQ_WHO_report_meeting.pdf?ua=1
2. Pan-American Health Organization. Prevention and Control of Communicable Diseases. (2009). Available from: http://new.paho.org/hq/dmdocuments/2009/nds-epi-profiles.pdf
3. World Health Organization. Action against Worms. (2008). Available from: http://www.who.int/neglected_diseases/preventive_chemotherapy/PCTNewsletter12_En.pdf?ua=1
4. World Health Organization. Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases: A Roadmap for Implementation. (2012). Available from: http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf
5. Olveda RM, Daniel BL, Ramirez BD, Aligui GD, Acosta LP, Fevidal P, et al. Schistosomiasis japonica in the Philippines: the long-term impact of population-based chemotherapy on infection, transmission, and morbidity. J Infect Dis (1996) 174(1):163-72. doi: 10.1093/infdis/174.1.163
6. Richards FO Jr, Eigege A, Miri ES, Jinadu MY, Hopkins DR. Integration of mass drug administration programmes in Nigeria: the challenge of schistosomiasis. Bull World Health Organ (2006) 84:673-6. doi:10.2471/BLT.06.029652
7. Reimert CM, Tukahebwa EM, Kabatereine NB, Dunne DW, Vennervald BJ. Assessment of Schistosoma mansoni induced intestina inflation by means of eosinophil cationic protein, eosinophil protein X and myeloperoxidase before and after treatment with praziquentel. Acta Trop (2008) 105(3):253-9. doi:10.1016/j.actatropica.2007.11.004
8. Olds GR, Olveda R, Wu G, Wiest P, McGarvey S, Aligui G, et al. Immunity and morbidity in Schistosomiasis japonicum infection. Am J Trop Med Hyg (1996) 55(Suppl 5):121-6.
9. Smithers SR, Terry RJ. Acquired resistance to experimental infections of Schistosoma mansoni in the albino rat. Parasitology (1965) 55(4):711-7.
10. Smithers SR, Terry RJ. The stimulation of acquired resistance to schistosome infection. Proc R Soc Med (1967) 60(2):169-70.
11. Almeida MS, Pinto RM, Noronha D, Katz N, Tendler M. Curative and protective activity in rabbits after reinfection with Schistosoma mansoni. A new model of immunity? J Parasitol (1989) 75:308-10. doi:10.2307/3282780
12. Smithers SR, Hackett F, Ali PO, Simpson AJ. Protective immunization of mice against Schistosoma mansoni with purified adult worm surface membranes. Parasite Immunol (1989) 11(4):301-18. doi:10.1111/j.1365-3024.1989.tb00669.x
13. Tendler M, Almeida MS, Pinto RM, Noronha D, Katz N. Schistosoma mansoni-new zealand rabbit model: resistance induced by infection followed by active immunization with protective antigen. J Parasitol (1991) 77(1):138-41. doi:10.2307/3282571
14. Tendler M, Pinto RM, Lima Ade O, Savino W, Katz N. Vaccination in murine schistosomiasis with adult worm-derived antigens: variables influencing protection outbred mice. Int J Parasitol (1991) 21(3):299-306. doi:10.1016/0020-7519(91)90031-2
15. Jeffs SA, Hagan P, Allen R, Correa-Oliveira R, Smithers SR, Simpson AJ. Molecular cloning and characterisation of the 22-kilodalton adult Schistosoma mansoni antigen recognised by antibodies from mice protectively vaccinated with isolated tegumental surface membranes. Mol Biochem Parasitol (1991) 46(1):159-67. doi:10.1016/0166-6851(91)90209-O
16. Knight M, Kelly C, Rodrigues V, Yi X, Wamachi A, Smithers SR, et al. A cDNA clone encoding part of the major 25,000-dalton surface membrane antigen of adult Schistosoma mansoni. Parasitol Res (1989) 75(4):280-6. doi:10.1007/BF00931812
17. Moser D, Tendler M, Griffiths G, Klinkert MQ. A 14-kDa Schistosoma mansoni polypeptide is homologous to a gene family of fatty acid binding proteins. J Biol Chem (1991) 266(13):8447-54.
18. Tendler M, Brito CA, Vilar MM, Serra-Freire N, Diogo CM, Almeida MS, et al. A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. Proc Natl Acad Sci U S A (1996) 93(1):269-73. doi:10.1073/pnas.93.1.269
19. Ramos CR, Spisni A, Oyama S Jr, Sforça ML, Ramos HR, Vilar MM, et al. Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: Structural and functional characterization of a vaccine candidate. Biochim Biophys Acta (2009) 1794(4):655-62. doi:10.1016/j.bbapap.2008.12.010
20. Ramos CR, Vilar MM, Nascimento AL, Ho PL, Thaumaturgo N, Edelenyi R. r-Sm14-pRSETA efficacy in experimental animals. Mem Inst Oswaldo Cruz (2001) 96(Suppl):131-5. doi:10.1590/S0074-02762001000900019
21. Ramos CR, Figueredo RC, Pertinhez TA, Vilar MM, do Nascimento AL, Tendler M, et al. Gene structure and M20T polymorphism of the Schistosoma mansoni Sm14 fatty acid-binding protein: molecular, functional and immunoprotection analysis. J Biol Chem (2003) 278(15):12745-51. doi:10.1016/j.bbapap.2008.12.010
22. Vilar MM, Barrientos F, Almeida M, Thaumaturgo N, Simpson A, Garratt R, et al. An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis. Vaccine (2003) 22(1):137-44. doi:10.1016/S0264-410X(03)00300-1
23. Varaldo PB, Leite LC, Dias WO, Miyaji EN, Torres FI, Gebara VC, et al. Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun (2004) 72(6):3336-43. doi:10.1128/IAI.72.6.3336-3343.2004
24. Varaldo PB, Miyaji EN, Vilar MM, Campos AS, Dias WO, Armôa GR, et al. Mycobacterial codon optimization of the gene encoding the Sm14 antigen of Schistosoma mansoni in recombinant Mycobacterium bovis Bacille Calmette-Guérin enhances protein expression but not protection against cercarial challenge in mice. FEMS Immunol Med Microbiol (2006) 48(1):132-9. doi:10.1111/j.1574-695X.2006.00133.x
25. Abreu PA, Miyasato PA, Vilar MM, Dias WO, Ho PL, Tendler M, et al. Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice. Infect Immun (2004) 72(10):5931-7. doi:10.1128/IAI.72.10.5931-5937.2004
26. Huang CJ, Damasceno LM, Anderson KA, Zhang S, Old LJ, Batt CA. A proteomic analysis of the Pichia pastoris secretome in methanol-induced cultures. Appl Microbiol Biotechnol (2011) 90(1):235-47. doi:10.1007/s00253-011-3118-5
27. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 5(10):e13677. doi:10.1371/journal.pone.0013677
28. Brito CF, Fonseca CT, Goes AM, Azevedo V, Simpson AJ, Oliveira SC. Human IgG1 and IgG3 recognition of Schistosoma mansoni 14kDa fatty acid-binding recombinant protein. Parasite Immunol (2000) 22(1):41-8.
29. Brito CF, Caldas IR, Coura Filho P, Correa-Oliveira R, Oliveira SC. CD4+ T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-γ and tumor necrosis factor-α in response to the recombinant 14kda Schistosoma mansoni fatty acid-binding protein. Scand J Immunol (2000) 51(6):595-601. doi:10.1046/j.1365-3083.2000.00710.x
30. Fonseca CT, Brito CF, Alves JB, Oliveira SC. l-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-γ and TNF-α dependent pathway. Vaccine (2004) 22(3-4):503-10. doi:10.1016/j.vaccine.2003.07.010
31. Fonseca CT, Cunha-Neto E, Goldberg AC, Kalil J, de Jesus AR, Carvalho EM, et al. Identification of paramyosin T cell epitopes associated with human resistance to Schistosoma mansoni reinfection. Microbes Infect (2005) 7(2):204-12. doi:10.1016/j.micinf.2004.10.012
32. Garcia TC, Fonseca CT, Pacifico LG, Durães Fdo V, Marinho FA, Penido ML, et al. Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice. Acta Trop (2008) 106(3):162-7. doi:10.1016/j.actatropica.2008.03.003
33. Rodríguez-Pérez J, Rodríguez-Medina JR, García-Blanco MA, Hillyer GV. Fasciola hepatica: molecular cloning, nucleotide sequence, and expression of a gene encoding a polypeptide homologous to a Schistosoma mansoni fatty acid-binding protein. Exp Parasitol (1992) 74(4):400-7. doi:10.1016/0014-4894(92)90202-L
34. Almeida MS, Torloni H, Lee-Ho P, Vilar MM, Thaumaturgo N, Simpson AJ, et al. Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14. Parasite Immunol (2003) 25(3):135-7. doi:10.1046/j.1365-3024.2003.00619.x
35. Mendes RE, Zafra R, Pérez-Ecija RA, Buffoni L, Martínez-Moreno A, Tendler M, et al. Evaluation of local immune response to Fasciola hepatica experimental infection in the liver and hepatic lymph nodes of goats immunized with Sm14 vaccine antigen. Mem Inst Oswaldo Cruz (2010) 105(5):698-705. doi:10.1590/S0074-02762010000500017
36. Muro A, Ramajo V, López J, Simón F, Hillyer GV. Fasciola hepatica: vaccination of rabbits with native and recombinant antigens related to fatty acid binding proteins. Vet Parasitol (1997) 69(3-4):219-29. doi:10.1016/S0304-4017(96)01131-4
37. López-Abán J, Casanueva P, Nogal J, Arias M, Morrondo P, Diez-Baños P, et al. Progress in the development of Fasciola hepatica vaccine using recombinant fatty acid binding protein with the adjuvant adaptation system ADAD. Vet Parasitol (2007) 145(3-4):287-96. doi:10.1016/j.vetpar.2006.12.017
38. Estuningsih SE, Smooker PM, Wiedosari E, Widjajanti S, Vaiano S, Partoutomo S, et al. Evaluation of antigens of Fasciola gigantic as vaccines against tropical fasciolosis in cattle. Int J Parasitol (1997) 27(11):1419-28. doi:10.1016/S0020-7519(97)00096-9
39. Nambi PA, Yadav SC, Raina OK, Sriveny D, Saini M. Vaccination of buffaloes with Fasciola gigantic recombinant fatty acid binding protein. Parasitol Res (2005) 97(2):129-35. doi:10.1007/s00436-005-1397-4
40. Kumar N, Anju V, Gaurav N, Chandra D, Samanta S, Gupta SC, et al. Vaccination of buffaloes with Fasciola gigantic recombinant glutathione S-transferase and fatty acid binding protein. Parasitol Res (2012) 110(1):419-26. doi:10.1007/s00436-011-2507-0
41. Vicente B, López-Abán J, Rojas-Caraballo J, Pérez Del Villar L, Hillyer GV, Martínez-Fernández AR, et al. A Fasciola hepatica-derived fatty acid binding protein induces protection against schistosomiasis caused by Schistosoma bovis using the adjuvant adaptation (ADAD) vaccination system. Exp Parasitol (2014) 145:145-51. doi:10.1016/j.exppara.2014.08.007
42. Rabia Aly I, Diab M, El-Amir AM, Hendawy M, Kadry S. Fasciola gigantic fatty acid binding protein (FABP) as a prophylactic agent against Schistosoma mansoni infection in CD1 mice. Korean J Parasitol (2012) 50(1):37-43. doi:10.3347/kjp.2012.50.1.37
43. Becker MM, Kalinna BH, Waine GJ, McManus DP. Gene cloning, overproduction and purification of a functionally active cytoplasmic fatty acid-binding protein (Sj-FABPC) from the human blood fluke Schistosoma japonicum. Gene (1994) 148(2):321-5. doi:10.1016/0378-1119(94)90706-4
44. Liu JM, Cai XZ, Lin JJ, Fu ZQ, Yang GZ, Shi FH, et al. Gene cloning, expression and vaccine testing of Schistosoma japonicum SjFABP. Parasite Immunol (2004) 26(8-9):351-8. doi:10.1111/j.0141-9838.2004.00720.x
45. Chabalgoity JA, Harrison JA, Esteves A, Demarco de Hormaeche R, Ehrlich R, Khan CM, et al. Expression and immunogenicity of an Echinococcus granulosus fatty acid-binding protein in live attenuated Salmonella vaccine strains. Infect Immun (1997) 65(6):2402-12.
46. Lee JS, Kim IS, Sohn WM, Lee J, Yong TS. A DNA vaccine encoding a fatty acid-binding protein of Clonorchis sinensis induces protective immune response in Sprague-Dawley rats. Scand J Immunol (2006) 63(3):169-76. doi:10.1111/j.1365-3083.2006.01721.x